The Impact of Empagliflozin on Inflammatory Markers in Adults with Type 2 Diabetes: A Retrospective Cohort.

Q2 Medicine

Medical Journal of the Islamic Republic of Iran Pub Date : 2024-09-11 eCollection Date: 2024-01-01 DOI:10.47176/mjiri.38.x

Hossein Samadanifard, Zahra Barati, Amir Hossein Ghanooni, Delaram Eskandari, Amir Ziaee, Haleh Chehrehgosha, Fatemeh Sarv, Shadi Zahraei

{"title":"The Impact of Empagliflozin on Inflammatory Markers in Adults with Type 2 Diabetes: A Retrospective Cohort.","authors":"Hossein Samadanifard, Zahra Barati, Amir Hossein Ghanooni, Delaram Eskandari, Amir Ziaee, Haleh Chehrehgosha, Fatemeh Sarv, Shadi Zahraei","doi":"10.47176/mjiri.38.x","DOIUrl":null,"url":null,"abstract":"Background: Inflammation plays a significant role in the development and progression of type 2 diabetes (T2D). Empagliflozin, an SGLT2 inhibitor, has shown some anti-inflammatory effects in patients with T2D. This study aimed to evaluate the impact of empagliflozin on some inflammatory markers in T2D.Methods: This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered P < 0.05.Results: After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; P = 0.025). However, the decrease in hs-CRP did not reach significance (P = 0.936). NLR did not show a significant reduction (P = 0.962), but there was a trend toward a significant decrease in PLR (107 ± 33 to 100 ± 35; P = 0.053). The neutrophil count did not change significantly (P = 0.247), but the lymphocyte count significantly increased (2.43 ± 7.85 to 2.57 ± 7.45 109/l; P = 0.014). Serum albumin showed a significant increase (42.8 ± 3.4 to 45.6 ± 3.2 g/l; P < 0.001), indicating a decrease in inflammation.Conclusion: Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.","PeriodicalId":18361,"journal":{"name":"Medical Journal of the Islamic Republic of Iran","volume":"38 ","pages":"x"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707716/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of the Islamic Republic of Iran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47176/mjiri.38.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Inflammation plays a significant role in the development and progression of type 2 diabetes (T2D). Empagliflozin, an SGLT2 inhibitor, has shown some anti-inflammatory effects in patients with T2D. This study aimed to evaluate the impact of empagliflozin on some inflammatory markers in T2D.

Methods: This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered P < 0.05.

Results: After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; P = 0.025). However, the decrease in hs-CRP did not reach significance (P = 0.936). NLR did not show a significant reduction (P = 0.962), but there was a trend toward a significant decrease in PLR (107 ± 33 to 100 ± 35; P = 0.053). The neutrophil count did not change significantly (P = 0.247), but the lymphocyte count significantly increased (2.43 ± 7.85 to 2.57 ± 7.45 109/l; P = 0.014). Serum albumin showed a significant increase (42.8 ± 3.4 to 45.6 ± 3.2 g/l; P < 0.001), indicating a decrease in inflammation.

Conclusion: Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.

查看原文本刊更多论文

恩格列净对成人2型糖尿病炎症标志物的影响：一项回顾性队列研究

背景：炎症在2型糖尿病（T2D）的发生和发展中起着重要作用。恩帕列净是一种SGLT2抑制剂，在T2D患者中显示出一定的抗炎作用。本研究旨在评估恩格列净对t2dm某些炎症标志物的影响。方法：这项回顾性单臂队列研究纳入了40例接受恩格列净治疗的T2D患者。炎症标志物如血清红细胞沉降率（ESR）、高敏c反应蛋白（hs-CRP）、中性粒细胞与淋巴细胞比率（NLR）、血小板与淋巴细胞比率（PLR）和血清白蛋白在基线和伊格列净治疗后12周进行评估。统计学分析采用配对样本t检验，以P < 0.05为统计学显著水平。结果：12周后，ESR显著降低（17.75±15.7 mm/hr至14.72±10.93 mm/hr）；P = 0.025)。而hs-CRP的降低无显著性意义（P = 0.936）。NLR无显著降低（P = 0.962）， PLR有显著降低的趋势（107±33 ~ 100±35）；P = 0.053)。中性粒细胞计数无显著变化（P = 0.247），淋巴细胞计数显著升高（2.43±7.85 ~ 2.57±7.45 109/l）；P = 0.014)。血清白蛋白显著升高（42.8±3.4 ~ 45.6±3.2 g/l）；P < 0.001)，表明炎症减轻。结论：恩格列净可降低成人T2D患者ESR、PLR，提高血清白蛋白和淋巴细胞计数，具有抗炎作用。监测炎症标志物可作为T2D患者治疗效果的指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊